All In Biotech

NDA 213137 · Global Blood Theraps

Oxbryta

Voxelotor · Oral · Hemoglobin S Polymerization Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 25, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

27

6 Phase 3, 0 recruiting

FAERS reports

22,311

9,624 serious, 419 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 26, 2023.

OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )

Mechanism: Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 17, 2021 Supplement 6 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 25, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • OXBRYTA · VOXELOTOR 300MG · TABLET, ORAL · Discontinued
  • OXBRYTA · VOXELOTOR 500MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Voxelotor" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sickle cell anaemia with crisis11,220
  • product dose omission issue5,172
  • diarrhoea3,187
  • off label use2,419
  • nausea2,017
  • headache1,691
  • abdominal pain upper1,171
  • pain1,086
  • therapy cessation1,040
  • fatigue1,008
  • abdominal discomfort970
  • therapy interrupted901

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20193
20203,384
20213,536
20229,276
20234,504
20241,436
2025142
202630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxbryta (Voxelotor)

2024 spending

$77.2M

Beneficiaries

1,374

6,389 claims

Per beneficiary

$56,178

$134.18 per unit

View as table
YearSpending
2020$47,599,743
2021$66,140,617
2022$77,713,365
2023$101,345,754
2024$77,189,159

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Global Blood Theraps

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.